FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:POU2AF1-BCO2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: POU2AF1-BCO2
FusionPDB ID: 67223
FusionGDB2.0 ID: 67223
HgeneTgene
Gene symbol

POU2AF1

BCO2

Gene ID

5450

83875

Gene namePOU class 2 homeobox associating factor 1beta-carotene oxygenase 2
SynonymsBOB1|OBF-1|OBF1|OCABB-DIOX-II|BCDO2
Cytomap

11q23.1

11q23.1

Type of geneprotein-codingprotein-coding
DescriptionPOU domain class 2-associating factor 1B-cell-specific coactivator OBF-1BOB-1OCA-BOCT-binding factor 1POU class 2 associating factor 1beta,beta-carotene 9',10'-oxygenaseb,b-carotene-9',10'-dioxygenasebeta,beta-carotene 9',10'-dioxygenase variant 1beta,beta-carotene 9',10'-dioxygenase variant 2beta,beta-carotene 9',10'-dioxygenase variant 3beta-carotene 9',10' oxygenasebeta-caroten
Modification date2020031320200313
UniProtAcc.

Q9BYV7

Main function of 5'-partner protein: FUNCTION: Asymmetrically cleaves beta-carotene at the 9',10' double bond resulting in the formation of beta-apo-10'-carotenal and beta-ionone. Besides beta-carotene, lycopene is also oxidatively cleaved. The apocarotenals formed by this enzyme may be the precursors for the biosynthesis of retinoic acid or exert unknown physiological effects. {ECO:0000269|PubMed:21106934}.
Ensembl transtripts involved in fusion geneENST idsENST00000393067, ENST00000515029, 
ENST00000357685, ENST00000361053, 
ENST00000393032, ENST00000438022, 
ENST00000526088, ENST00000531169, 
ENST00000532593, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score4 X 3 X 4=484 X 3 X 4=48
# samples 44
** MAII scorelog2(4/48*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/48*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: POU2AF1 [Title/Abstract] AND BCO2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: POU2AF1 [Title/Abstract] AND BCO2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)POU2AF1(111228170)-BCO2(112084447), # samples:2
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneBCO2

GO:0016119

carotene metabolic process

11278918

TgeneBCO2

GO:0016121

carotene catabolic process

21302131

TgeneBCO2

GO:0055114

oxidation-reduction process

21302131



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:111228170/chr11:112084447)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across POU2AF1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across BCO2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000393067POU2AF1chr11111228170-ENST00000357685BCO2chr11112084447+25729714311516361
ENST00000393067POU2AF1chr11111228170-ENST00000393032BCO2chr11112084447+25639714311516361
ENST00000393067POU2AF1chr11111228170-ENST00000361053BCO2chr11112084447+17849714311516361
ENST00000393067POU2AF1chr11111228170-ENST00000438022BCO2chr11112084447+17609714311516361
ENST00000393067POU2AF1chr11111228170-ENST00000526088BCO2chr11112084447+17609714311498355
ENST00000393067POU2AF1chr11111228170-ENST00000532593BCO2chr11112084447+16339714311516361
ENST00000393067POU2AF1chr11111228170-ENST00000531169BCO2chr11112084447+22999714311516361

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000393067ENST00000357685POU2AF1chr11111228170-BCO2chr11112084447+0.0026688930.99733114
ENST00000393067ENST00000393032POU2AF1chr11111228170-BCO2chr11112084447+0.002695030.9973049
ENST00000393067ENST00000361053POU2AF1chr11111228170-BCO2chr11112084447+0.0043576710.9956423
ENST00000393067ENST00000438022POU2AF1chr11111228170-BCO2chr11112084447+0.0047374280.9952625
ENST00000393067ENST00000526088POU2AF1chr11111228170-BCO2chr11112084447+0.0043223810.99567765
ENST00000393067ENST00000532593POU2AF1chr11111228170-BCO2chr11112084447+0.00572430.99427575
ENST00000393067ENST00000531169POU2AF1chr11111228170-BCO2chr11112084447+0.003218210.9967818

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for POU2AF1-BCO2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
POU2AF1chr11111228170BCO2chr11112084447971180LTYASPPLITNVTVHNSAAKSFPRRF

Top

Potential FusionNeoAntigen Information of POU2AF1-BCO2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
POU2AF1-BCO2_111228170_112084447.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
POU2AF1-BCO2chr11111228170chr11112084447971HLA-B15:18TVHNSAAKSF0.91170.6651222
POU2AF1-BCO2chr11111228170chr11112084447971HLA-B15:10TVHNSAAKSF0.73150.54991222
POU2AF1-BCO2chr11111228170chr11112084447971HLA-B15:37TVHNSAAKSF0.65690.51391222
POU2AF1-BCO2chr11111228170chr11112084447971HLA-B38:01TVHNSAAKSF0.36360.96341222
POU2AF1-BCO2chr11111228170chr11112084447971HLA-B38:02TVHNSAAKSF0.32890.97111222
POU2AF1-BCO2chr11111228170chr11112084447971HLA-B38:05TVHNSAAKSF0.36360.96341222

Top

Potential FusionNeoAntigen Information of POU2AF1-BCO2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
POU2AF1-BCO2_111228170_112084447.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0415PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0415SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0427PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0427SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0436PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0436SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0437PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0437SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0440PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0442PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0450PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0451PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0453PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0453SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0454PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0455PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0455SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0456PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0458PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0458SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0459PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0465PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0465SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0468PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0470PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0473PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0473SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0478PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0478SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0479PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0488PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0901NVTVHNSAAKSFPRR1025
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0901TNVTVHNSAAKSFPR924
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0903NVTVHNSAAKSFPRR1025
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0904NVTVHNSAAKSFPRR1025
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0904TNVTVHNSAAKSFPR924
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0905NVTVHNSAAKSFPRR1025
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0906NVTVHNSAAKSFPRR1025
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0906TNVTVHNSAAKSFPR924
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0906ITNVTVHNSAAKSFP823
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0907NVTVHNSAAKSFPRR1025
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0907TNVTVHNSAAKSFPR924
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0909NVTVHNSAAKSFPRR1025
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-0909TNVTVHNSAAKSFPR924
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-1367SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-1447SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-1457PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB1-1457SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0201SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0201ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0201YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0201PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0202SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0202ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0202YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0202PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0204SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0204ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0204PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0204YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0205SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0205ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0205PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0205YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0209SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0210SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0210ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0210YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0210PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0211SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0211ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0211YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0211PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0212SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0212ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0212YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0212PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0213SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0213ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0213YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0213PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0214SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0214ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0214YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0214PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0215SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0215ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0215YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0215PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0216SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0216ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0216YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0217SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0217ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0217YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0217PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0218SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0218ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0218YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0218PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0219SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0219ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0219YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0219PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0220SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0220ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0220YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0220PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0221SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0222SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0222ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0222YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0222PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0223SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0223ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0223YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0223PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0224SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0224ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0224YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0224PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0225SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0225ASPPLITNVTVHNSA318
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0225YASPPLITNVTVHNS217
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0225PPLITNVTVHNSAAK520
POU2AF1-BCO2chr11111228170chr11112084447971DRB3-0301SPPLITNVTVHNSAA419
POU2AF1-BCO2chr11111228170chr11112084447971DRB5-0106ITNVTVHNSAAKSFP823
POU2AF1-BCO2chr11111228170chr11112084447971DRB5-0202ITNVTVHNSAAKSFP823
POU2AF1-BCO2chr11111228170chr11112084447971DRB5-0204ITNVTVHNSAAKSFP823

Top

Fusion breakpoint peptide structures of POU2AF1-BCO2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6766PLITNVTVHNSAAKPOU2AF1BCO2chr11111228170chr11112084447971

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of POU2AF1-BCO2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6766PLITNVTVHNSAAK-7.9962-8.1096
HLA-B14:023BVN6766PLITNVTVHNSAAK-5.70842-6.74372
HLA-B52:013W396766PLITNVTVHNSAAK-6.83737-6.95077
HLA-B52:013W396766PLITNVTVHNSAAK-4.4836-5.5189
HLA-A11:014UQ26766PLITNVTVHNSAAK-10.0067-10.1201
HLA-A11:014UQ26766PLITNVTVHNSAAK-9.03915-10.0745
HLA-A24:025HGA6766PLITNVTVHNSAAK-6.56204-6.67544
HLA-A24:025HGA6766PLITNVTVHNSAAK-5.42271-6.45801
HLA-B44:053DX86766PLITNVTVHNSAAK-7.85648-8.89178
HLA-B44:053DX86766PLITNVTVHNSAAK-5.3978-5.5112
HLA-A02:016TDR6766PLITNVTVHNSAAK-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of POU2AF1-BCO2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
POU2AF1-BCO2chr11111228170chr111120844471222TVHNSAAKSFACGGTCCATAATTCAGCAGCCAAATCTTTC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
POU2AF1-BCO2chr11111228170chr111120844471025NVTVHNSAAKSFPRRAATGTCACGGTCCATAATTCAGCAGCCAAATCTTTCCCTCGAAGG
POU2AF1-BCO2chr11111228170chr11112084447217YASPPLITNVTVHNSTATGCCTCTCCGCCACTCATCACCAATGTCACGGTCCATAATTCA
POU2AF1-BCO2chr11111228170chr11112084447318ASPPLITNVTVHNSAGCCTCTCCGCCACTCATCACCAATGTCACGGTCCATAATTCAGCA
POU2AF1-BCO2chr11111228170chr11112084447419SPPLITNVTVHNSAATCTCCGCCACTCATCACCAATGTCACGGTCCATAATTCAGCAGCC
POU2AF1-BCO2chr11111228170chr11112084447520PPLITNVTVHNSAAKCCGCCACTCATCACCAATGTCACGGTCCATAATTCAGCAGCCAAA
POU2AF1-BCO2chr11111228170chr11112084447823ITNVTVHNSAAKSFPATCACCAATGTCACGGTCCATAATTCAGCAGCCAAATCTTTCCCT
POU2AF1-BCO2chr11111228170chr11112084447924TNVTVHNSAAKSFPRACCAATGTCACGGTCCATAATTCAGCAGCCAAATCTTTCCCTCGA

Top

Information of the samples that have these potential fusion neoantigens of POU2AF1-BCO2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
UCECPOU2AF1-BCO2chr11111228170ENST00000393067chr11112084447ENST00000357685TCGA-KP-A3VZ-01A

Top

Potential target of CAR-T therapy development for POU2AF1-BCO2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to POU2AF1-BCO2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to POU2AF1-BCO2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource